Pesquisa e inovação em saúde: uma discussão a partir da literatura sobre economia da tecnologia

Albuquerque, Eduardo da Motta e; Souza, Sara Gonçalves Antunes de; Baessa, Adriano Ricardo

doi:10.1590/s1413-81232004000200007

Cited by 32 publications

(27 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With regard to infectious and parasitic diseases, only rifapentine and terizodone are specific for tuberculosis. A large gap exists between the burden of disease and investments in R&D and innovation; "market forces" are not powerful enough to ensure the development of drugs to treat diseases that affect the poor, who usually cannot afford treatment (56).…”

Section: Meeting the Burden Of Diseasementioning

confidence: 99%

New drugs in Brazil: do they meet Brazilian public health needs?

Vidotti¹,

Castro²,

Calil³

2008

Rev Panam Salud Publica

View full text Add to dashboard Cite

Objectives. To describe the new drugs marketed in Brazil during the period 2000-2004, compare Conclusions. A mismatch occurs between public health needs and the new drugs launched on the Brazilian market. Not only did the number of new drugs decrease in the study period, but only a few were actually new in therapeutic terms. Developing countries must acquire expertise in research and development to strengthen their capacity to innovate and produce the drugs they need.New drugs, drugs of interest in public health, pharmaceutical drug trade, innovation, pharmacoepidemiology, Brazil. ABSTRACTResearch and development (R&D) are essential to generating health products that combat diseases. R&D conducted by the pharmaceutical industry addresses the needs of wealthier countries, but all too often, underprivileged populations in poorer areas of the world have few or no treatment options and restricted access to treatments that do exist. The power held by the pharmaceutical industry is, to varying degrees, lost when the market is insufficiently wide or steady, or when effective public policies are not in place to promote R&D. Given this context, the current situation regarding the launching of new drugs needs to be acknowledged and addressed by policymakers, managers, and researchers in public and private institutions alike, if availability for actual public health needs is to be improved.

show abstract

Section: Meeting the Burden Of Diseasementioning

confidence: 99%

New drugs in Brazil: do they meet Brazilian public health needs?

Vidotti¹,

Castro²,

Calil³

2008

Rev Panam Salud Publica

View full text Add to dashboard Cite

show abstract

“…The link between national innovation systems and increases in social welfare and inclusion is a terrain yet to be explored. In Brazil, prominence needs to be given to the research by Albuquerque et al, 2 who discussed the possibilities in the health field of "combined construction of an innovation system and a social welfare system" and the studies by Gadelha 3 and Gadelha et al, 4 who coined and developed the concept of the "productive health complex".…”

Section: The Challenge Of Maturing the National Innovation System Formentioning

confidence: 99%

Pesquisa em saúde no Brasil: contexto e desafios

Guimarães

2006

Rev. Saúde Pública

View full text Add to dashboard Cite

The deficiencies in Brazilian science and technology policies with regard to the challenges of the twenty-first century are discussed, while acknowledging that these policies have in some respects been very successful. The importance of health research within the framework of general endeavors in science, technology and innovation in this country is also demonstrated. The distribution of research around the world is then summarized, and a specific position is claimed for Brazil, along with some other countries, within the global panorama. Some elements needed for maturation of the sectoral system for health innovation are discussed. Finally, the need for the presence of the Ministry of Health within the panorama of health research, for this maturation process to take place adequately, is discussed.

show abstract

“…Other authors 42 call attention to the fact that it is precisely the poorest and most underprivileged areas that have few or no health care options; and that even when they exist, the existing treatments are not necessarily accessible. The importance of each country's internal scientific effort is highlighted by the argument that different epidemiological profiles lead to different demands on the innovation systems 43 . Along the same line, authors 12 have highlighted the unfavorable position of less developed countries as a function of the lack of specific medicines for their populations' needs.…”

Section: Public Policies For Innovationmentioning

confidence: 99%

Windows of opportunities and technological innovation in the Brazilian pharmaceutical industry

2016

View full text Add to dashboard Cite

The Brazilian pharmaceutical industry is heavily dependent on external sources of inputs, capital, and technology. However, the emergence of technological opportunities and the development of biotechnology and the decline of the patent boom and resulting advances by generic drugs have opened windows of opportunities for the local industry. The article examines the Brazilian industry's innovative behavior vis-à-vis these opportunities, showing that although the industry as a whole invests little in innovation, a few large Brazilian companies have expanded their market share and stepped up their investments in research and development, supported by public policies for innovation.

show abstract

Pesquisa e inovação em saúde: uma discussão a partir da literatura sobre economia da tecnologia

Cited by 32 publications

References 22 publications

New drugs in Brazil: do they meet Brazilian public health needs?

New drugs in Brazil: do they meet Brazilian public health needs?

Pesquisa em saúde no Brasil: contexto e desafios

Windows of opportunities and technological innovation in the Brazilian pharmaceutical industry

Contact Info

Product

Resources

About